References
- 1. Bielekova B. Daclizumab therapy for multiple sclerosis. Neurotherapeutics. 2013;10:55-67.
- 2. Krueger JG, Kircik L, Hougeir F, et al. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. Adv Ther. 2016;33:1231-1245.
- 3. Cortese I, Ohayon J, Fenton K, et al. Cutaneous adverse events in multiple sclerosis patients treated with daclizumab. Neurology. 2016;86:847-855.
- 4. Kircik L, Krueger J, Lebwohl M, et al. Incidence, severity, duration, and treatment of cutaneous adverse events in the DECIDE study of daclizumab HYP versus intramuscular interferon beta-1a in patients with relapsingremitting multiple sclerosis. Mult Scler. 2015;21:251-252.
- 5. Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381:2167-2175.
- 6. Diao L, Hang Y, Othman AA, et al. Population PK-PD analyses of CD25 occupancy, CD56bright NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis. Br J Clin Pharmacol. 2016;82:1333-1342.
- 7. Michel T, Poli A, Cuapio A et al. Human CD56bright NK Cells: An Update. J Immunol. 2016; 196:2923-2931.